Exogenous phosphatidylglucoside alleviates cognitive impairment by improvement of neuroinflammation, and neurotrophin signaling.

Of note, isotope-labeled PtdGlc was observed in the brain of SP 13 sp C6-PtdGlc treated mice, which demonstrated that PtdGlc could reach to brain (Figure S4). Dear Editor, Alzheimer's disease (AD) is a commonly progressive disorder of neurodegenerative disease.1 Until now, no approach to treat the pathological progression of AD has been proven to be effective.1 Our data favored that the treatment of phosphatidylglucoside (PtdGlc), a novel glucosylated lipid enriched in the brain, protects against A and tau pathology, cognition deficits in APP/PS1 mice, and alleviates neuroinflammation through activation of PPAR and restoration of the neurotrophin signaling. Activated microglia cells and astrocytes can trigger inflammatory processes and regulate neuroinflammation in the brain.8 ASC and Caspase 1 levels were reduced by PtdGlc treatment in APP/PS1 mice, while NLRP3 expression was unchanged. To examine whether the PtdGlc reached to brain, the mice was injected with stable isotope-labeled PtdGlc ( SP 13 sp C6-D-PtdGlc) via the tail vein. [Extracted from the article]